Aslan Pharmaceuticals Pte. Ltd., of Singapore, said it is undertaking a strategic corporate restructuring in order to focus its resources on lead clinical programs including: varlitinib in biliary tract cancer (BTC); ASLAN-003, targeting acute myeloid leukemia (AML); and ASLAN-004, focused on atopic dermatitis.